Cargando…
Factors Affecting the Duration of Phase 1 of Dexamethasone-Immunosuppressant Pulse Therapy for Pemphigus Group of Disorders: A 10-Year Retrospective Study in a Tertiary Care Center
CONTEXT: Dexamethasone-immunosuppressant pulse therapy introduced by Pasricha et al. in 1981 as a treatment for long-term remission in pemphigus group of disorders has gained wide acceptance in many places, especially India. Since the overall duration of treatment is determined by the duration of ph...
Autores principales: | Mundakkat, Vidya, Sridharan, Rajiv |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6232981/ https://www.ncbi.nlm.nih.gov/pubmed/30505779 http://dx.doi.org/10.4103/idoj.IDOJ_74_18 |
Ejemplares similares
-
Dexamethasone-cyclophosphamide pulse therapy outcomes comparing pemphigus vulgaris and pemphigus foliaceus groups in a Brazilian cohort study()
por: Fontenelle, Ludmilla Figueiredo, et al.
Publicado: (2023) -
Severe COVID-19 along with Cytokine Storm in Pemphigus Vulgaris Managed Successfully with Dexamethasone Pulse Therapy
por: Pradhan, Swetalina, et al.
Publicado: (2021) -
A Comparative Study to Evaluate the Efficacy and Cost of Rituximab versus Dexamethasone Cyclophosphamide Pulse in Patients of Pemphigus Vulgaris
por: Das, Sudip, et al.
Publicado: (2021) -
Pulse Therapy in Pemphigus: Ready Reckoner
por: Abraham, Anil, et al.
Publicado: (2016) -
Pulse therapy in pemphigus: report of 11 cases
por: Fernandes, Nurimar Conceição, et al.
Publicado: (2013)